AU2002364954A1 - ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS - Google Patents

ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Info

Publication number
AU2002364954A1
AU2002364954A1 AU2002364954A AU2002364954A AU2002364954A1 AU 2002364954 A1 AU2002364954 A1 AU 2002364954A1 AU 2002364954 A AU2002364954 A AU 2002364954A AU 2002364954 A AU2002364954 A AU 2002364954A AU 2002364954 A1 AU2002364954 A1 AU 2002364954A1
Authority
AU
Australia
Prior art keywords
blys
antibodies
immunospecifically bind
immunospecifically
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002364954A
Other versions
AU2002364954A8 (en
Inventor
Steven C. Barash
Gil H. Choi
David Hilbert
Steven M. Ruben
Tristan J. Vaughan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2002364954A8 publication Critical patent/AU2002364954A8/en
Publication of AU2002364954A1 publication Critical patent/AU2002364954A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002364954A 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS Abandoned AU2002364954A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US60/331,469 2001-11-16
US34081701P 2001-12-19 2001-12-19
US60/340,817 2001-12-19
PCT/US2002/036496 WO2003055979A2 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Publications (2)

Publication Number Publication Date
AU2002364954A8 AU2002364954A8 (en) 2003-07-15
AU2002364954A1 true AU2002364954A1 (en) 2003-07-15

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002364954A Abandoned AU2002364954A1 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Country Status (4)

Country Link
EP (1) EP1456347A4 (en)
AU (1) AU2002364954A1 (en)
CA (1) CA2467521A1 (en)
WO (1) WO2003055979A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
CN100340292C (en) 1999-01-25 2007-10-03 比奥根艾迪克Ma公司 BAFF, inhibitors thereof and their use in modulation of B-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
EP2314694A3 (en) 1999-08-17 2013-12-11 Biogen Idec MA Inc. BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
KR20060027801A (en) 2003-06-05 2006-03-28 제넨테크, 인크. Combination therapy for b cell disorders
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
KR100924044B1 (en) 2004-03-31 2009-10-27 캐논 가부시끼가이샤 Structure for capturing target substance
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20080050381A1 (en) * 2004-08-31 2008-02-28 Tsutomu Takeuchi Antihuman Baff Antibody
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2008119042A2 (en) 2007-03-27 2008-10-02 Zymogenetics, Inc. Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN103421113B (en) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 Anti- BLyS antibody
CN104045713B (en) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 The monoclonal antibody of anti-Blys a kind of and pharmaceutical composition containing the antibody
CN109311988A (en) * 2016-07-06 2019-02-05 上海开拓者生物医药有限公司 A kind of BlyS antibody and its preparation method and application
EP3576790A4 (en) 2017-02-01 2020-12-23 Yale University Treatment of diuretic resistance
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028830T2 (en) * 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS
CA2408617A1 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU6842701A (en) * 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
JP2004533997A (en) * 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Antibodies that bind both BCMA and TACI

Also Published As

Publication number Publication date
CA2467521A1 (en) 2003-07-10
AU2002364954A8 (en) 2003-07-15
EP1456347A2 (en) 2004-09-15
EP1456347A4 (en) 2006-08-02
WO2003055979A2 (en) 2003-07-10
WO2003055979A3 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
AU2002364954A1 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
EP1572874A3 (en) Antibodies that immunospecifically bind to trail receptors
CY2012003I1 (en) ANTIBODIES THAT BIND IMMUNOSPECIFICALLY TO BLYS
EP1465925A4 (en) Antibodies that immunospecifically bind to trail receptors
HK1075470A1 (en) Antibodies that immunospecifically bind to trail receptors
EP2270052B8 (en) Antibodies to OPGL
IL213564A0 (en) Antibodies to vla-1
EP1494693A4 (en) Cripto-specific antibodies
AU2002359659A1 (en) Cross reference to related application
AU2003234706A1 (en) Antibodies that specifically bind to tl5
AU2003218456A1 (en) Antibodies that specifically bind to gmad
AU2003240822A1 (en) Antibodies that specifically bind to neurokinin b
AU2003256299A1 (en) Antibodies that specifically bind to reg iv
AU2002351374A1 (en) Antibodies to treat cancer
AU2003302822A1 (en) Antibodies to treat cancer
AU2606700A (en) Saccharides linked to compounds that bind cell-surface peptides or proteins
AU2002352676A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2003288809A1 (en) Peptides that bind of the vegfr-2
AU2003259835A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2001297702A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2002365894A1 (en) Antibodies to magmas and uses thereof
AU2003228483A8 (en) Antibodies that specifically bind to tr2
AU2002953290A0 (en) Monoclonal antibodies to cyclospora
AU2002248038A1 (en) Human polyclonal antibody compositions
AU2002304743A1 (en) Cancer treatment by using fap-alpha specific antibodies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase